Release 5

This page is part of the FHIR Specification (v5.0.0: R5 - STU). This is the current published version in it's permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4 R3

Example PlanDefinition/KDN5 (Narrative)

Clinical Decision Support Work GroupMaturity Level: N/AStandards Status: InformativeCompartments: No defined compartments

This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile PlanDefinition.

National Comprehensive Cancer Network

Chemotherapy Order Template

Kidney Cancer

Gemcitabine/CARBOplatin

 KDN5

INDICATION:

Metastatic or Relapsed – Collecting Duct/Medullary Subtypes

REFERENCES:

  1. NCCN Guidelines® for Kidney Cancer. V.3.2015.
  2. Oudard S, et al. J Urol. 2007;177(5):1698-702. a

NCCN SUPPORTIVE CARE:

  1. Emetic Risk:
    Day 1 Moderate
    Day 8 Low
  2. Fever Neutropenia Risk:
    Refer to NCCN Guidelines for Myeloid Growth Factors. V.2.2014

CHEMOTHERAPY REGIMEN

21-day cycle for 6 cycles

  • Gemcitabine 1250 mg/m 2 IV over 30 minutes on Days 1 and 8
  • CARBOplatin AUC 5 IV over 30 minutes on Day 1

 

 

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.